瑞利珠单抗（Cinqair）：一种用于嗜酸性粒细胞型重度哮喘的白细胞介素-5拮抗剂。
Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype.
作者信息
Hom Selina, Pisano Michele
出版信息
P T. 2017 Sep;42(9):564-568.
Abstract
Reslizumab (Cinqair), an interleukin-5 antagonist for severe eosinophilic asthma.
摘要
瑞利珠单抗（Cinqair），一种用于治疗重度嗜酸性粒细胞性哮喘的白细胞介素-5拮抗剂。
相似文献
1
2
Reslizumab in Eosinophilic Asthma: A Review.瑞利珠单抗在嗜酸性粒细胞性哮喘中的应用：综述。
Drugs. 2017 May;77(7):777-784. doi: 10.1007/s40265-017-0740-2.
3
Reslizumab (Cinqair) for severe eosinophilic asthma.瑞利珠单抗（Cinqair）用于治疗重度嗜酸性粒细胞性哮喘。
Med Lett Drugs Ther. 2016 Jun 20;58(1497):81-2.
4
Reslizumab: First Global Approval.雷西珠单抗：全球首次获批。
Drugs. 2016 May;76(8):907-11. doi: 10.1007/s40265-016-0583-2.
5
Reslizumab (Cinqair) for Eosinophilic Asthma.瑞利珠单抗（Cinqair）用于治疗嗜酸性粒细胞性哮喘。
Am Fam Physician. 2017 Nov 15;96(10):671-672.
6
[Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma].[瑞利珠单抗治疗重度过敏性嗜酸性粒细胞性哮喘患者的临床与经济学分析]
Ter Arkh. 2019 Dec 15;91(12):47-56. doi: 10.26442/00403660.2019.12.000452.
7
Reslizumab in the management of poorly controlled asthma: the data so far.瑞利珠单抗用于控制不佳哮喘的管理：目前的数据
J Asthma Allergy. 2016 Aug 31;9:155-62. doi: 10.2147/JAA.S94164. eCollection 2016.
8
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?瑞利珠单抗与嗜酸性粒细胞性哮喘：离精准医学更近一步了吗？
Front Immunol. 2017 Mar 10;8:242. doi: 10.3389/fimmu.2017.00242. eCollection 2017.
9
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy.接受瑞利珠单抗及全球哮喘防治创议（GINA）第4或5步治疗的嗜酸性粒细胞性哮喘患者的分层
ERJ Open Res. 2017 Aug 17;3(3). doi: 10.1183/23120541.00004-2017. eCollection 2017 Jul.
10
Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.瑞利珠单抗治疗嗜酸性粒细胞性哮喘患者的长期安全性和疗效。
J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1572-1581.e3. doi: 10.1016/j.jaip.2017.08.024.
引用本文的文献
1
Targeted Biologic Therapies in Severe Asthma: Mechanisms, Biomarkers, and Clinical Applications.重度哮喘的靶向生物疗法：作用机制、生物标志物及临床应用
Pharmaceuticals (Basel). 2025 Jul 10;18(7):1021. doi: 10.3390/ph18071021.
2
Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.嗜酸性粒细胞驱动型与嗜酸性粒细胞相关型重度哮喘：靶向治疗的实际意义
Int J Mol Sci. 2025 Feb 18;26(4):1729. doi: 10.3390/ijms26041729.
3
TREM1 is involved in the mechanism between asthma and lung cancer by regulating the Toll‑like receptor signaling pathway.触发受体表达分子1（TREM1）通过调节Toll样受体信号通路参与哮喘与肺癌之间的机制。
Oncol Lett. 2023 Nov 13;27(1):16. doi: 10.3892/ol.2023.14149. eCollection 2024 Jan.
4
Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.推进大疱性类天疱疮的治疗：新型治疗靶点和方法的全面综述。
Clin Rev Allergy Immunol. 2023 Dec;65(3):331-353. doi: 10.1007/s12016-023-08973-1. Epub 2023 Oct 28.
5
Evidence-Based Approach of Biologic Therapy in Bronchial Asthma.支气管哮喘生物治疗的循证方法
J Clin Med. 2023 Jun 27;12(13):4321. doi: 10.3390/jcm12134321.
6
Safety of Biologics for Atopic Diseases During Pregnancy.妊娠期特应性疾病生物制剂的安全性。
J Allergy Clin Immunol Pract. 2022 Dec;10(12):3149-3155. doi: 10.1016/j.jaip.2022.08.013. Epub 2022 Aug 18.
7
Treating severe asthma: Targeting the IL-5 pathway.治疗严重哮喘：靶向 IL-5 通路。
Clin Exp Allergy. 2021 Aug;51(8):992-1005. doi: 10.1111/cea.13885. Epub 2021 May 21.
8
Changes in Type 2 Biomarkers After Anti-IL5 Treatment in Patients With Severe Eosinophilic Asthma.重度嗜酸性粒细胞性哮喘患者接受抗IL-5治疗后2型生物标志物的变化
Allergy Asthma Immunol Res. 2021 Mar;13(2):330-338. doi: 10.4168/aair.2021.13.2.330.
9
Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease.靶向治疗慢性阻塞性肺疾病的衰老途径。
Int J Mol Sci. 2020 Sep 21;21(18):6924. doi: 10.3390/ijms21186924.
10
Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma.生物学与治疗学的交叉点：成人哮喘的 2 型靶向治疗。
Lancet. 2020 Feb 1;395(10221):371-383. doi: 10.1016/S0140-6736(19)33005-3.
本文引用的文献
1
Diagnosis and management of eosinophilic asthma: a US perspective.嗜酸性粒细胞性哮喘的诊断与管理：美国视角
J Asthma Allergy. 2014 Apr 11;7:53-65. doi: 10.2147/JAA.S39119. eCollection 2014.
2
Inflammatory cells in asthma: mechanisms and implications for therapy.
J Allergy Clin Immunol. 2003 Jan;111(1 Suppl):S5-S12; discussion S12-7. doi: 10.1067/mai.2003.22.
Zotero 插件